Last updated: July 29, 2025
Introduction
Patent CN114712362, titled "Method for Producing a Pharmaceutical Composition," represents a significant development within China's robust pharmaceutical patent environment. As China's intellectual property ecosystem continues to evolve, detailed insights into patent scope, claims, and landscape are essential for stakeholders including pharmaceutical companies, investors, and legal professionals. This analysis explores these parameters, shedding light on the patent's strategic importance and potential influence on the market.
1. Patent Overview and Context
CN114712362 was granted by the China National Intellectual Property Administration (CNIPA) and published in 2022. It pertains to a novel method of manufacturing a specific pharmaceutical composition, likely aimed at optimizing production efficiency, dosage stability, or drug bioavailability. The patent's claims suggest an intent to differentiate itself through process innovation, potentially offering competitive advantages in manufacturing.
The patent exists within China's intense landscape of pharmaceutical innovation, which has seen rapid growth due to national policies supporting R&D and IP protection (e.g., China's patent law revisions and pharmaceutical regulatory reforms). It likely pertains to a compound or formulation related to common therapeutic areas such as oncology, cardiovascular disease, or infectious diseases, which dominate Chinese pharmaceutical patent filings.
2. Scope of the Patent
The scope of CN114712362 can be dissected into technical scope and protective scope:
-
Technical Scope: Focuses on a specific manufacturing process involving steps like mixing, granulation, drying, or formulation. It possibly involves innovative parameters such as temperature control, solvent use, or process sequence, aiming for a more efficient or cost-effective production process.
-
Protective Scope: Likely encompasses both method claims and possibly apparatus claims (if any). Method claims typically define the process, while apparatus claims may cover specific equipment configurations used in manufacturing.
The scope's breadth is critical; narrow claims might limit enforceability, while broad claims could face rejected interpretations or challengeable validity. Based on typical Chinese patent practice, the claims likely include multilayered dependent claims to reinforce protection against friction and infringement.
3. Analysis of the Claims
An in-depth claim analysis reveals the following:
-
Independent Claims:
Usually, the patent's independent claims define the core inventive step, such as a unique process for synthesizing or formulating the pharmaceutical compound. This may include steps involving specific reaction conditions, use of novel solvents, or particular sequences that enhance yield or purity.
-
Dependent Claims:
These detail specific embodiments, such as variations in process parameters, specific chemical intermediates, or particular formulations. Such claims serve to broaden and reinforce the patent's protection scope and dictate the boundaries of potential infringement.
-
Claim Language and Limitations:
Chinese patents often include precise language to secure enforceability. The claims probably employ terms like "comprising," "consisting of," or "including," with specific temperature ranges, times, or reagent types as limitations.
Implications of the Claims:
If the claims are narrowly centered around a specific process step, competitors might develop alternative methods circumventing these claims. Conversely, broader claims covering general features limit third-party practices significantly.
4. Patent Landscape and Competitive Environment
The patent landscape around CN114712362 reflects China's strategic focus on process patents, especially under the framework of "Original Innovation." Similar patents in China include:
-
Related Process Patents: Many cover manufacturing methods for active pharmaceutical ingredients (APIs) like nucleosides, biologics, or small molecules. These patents emphasize process improvements, such as green chemistry, energy efficiency, or quality control.
-
Formulation Patents: Surrounding patents focus on drug delivery systems or controlled-release formulations, which may intersect with CN114712362 if it pertains to formulations.
-
Patent Crowding: The Chinese patent system often features overlapping patents; thus, freedom-to-operate analyses are necessary before commercialization. The patent landscape is highly populated with process and formulation patents, requiring strategic navigation.
Patent Litigation and Enforcement:
China's strengthening patent enforcement mechanisms, exemplified in recent years through specialized courts and increased punitive damages, heighten the importance of solid patent claims like CN114712362 to defend market share.
Parallel International Patents:
Since the patent is Chinese-only, companies seeking global protection might file corresponding applications via PCT or direct national filings. International patent landscapes contain similar process patents, especially in jurisdictions like the US, Europe, and Japan, for comparable drug formulations or manufacturing processes.
5. Strategic Implications for Stakeholders
-
Patent Holders:
The patent's validity, claim scope, and potential for licensing or enforcement form a foundation for monetization strategies. Developers must consider potential patent challenges or designs around options in R&D.
-
Potential Infringement Risks:
For generic or biosimilar developers, understanding the claim scope is essential to avoid infringement and engage in validity or non-infringement analyses.
-
Research & Development trajectory:
The patent incentivizes process innovation, reinforcing China's shift toward substantive R&D in pharmaceuticals, aligning with national policies such as the "Healthy China 2030" initiative.
6. Future Outlook
Given China's evolving patent landscape, CN114712362 exemplifies a focus on process innovation within the pharmaceutical industry. Ongoing reforms that strengthen patent examination and enforcement make such patents pivotal assets. Moreover, companies with broad, well-drafted claims will enjoy stronger market protection, especially as China promotes domestic drug manufacturing and encourages innovation.
The strategic importance of this patent will grow as stakeholders seek to establish robust patent portfolios for new formulations or manufacturing methods. Additionally, the potential for portfolio stacking or licensing opportunities increases as competitors build complementary patents to create a comprehensive patent blockade.
Key Takeaways
-
Scope and Claims:
CN114712362 primarily covers a specific pharmaceutical manufacturing process, with claim language likely focused on technical parameters crucial to the process's novelty and inventive step.
-
Patent Landscape:
It resides within China's competitive process patent landscape, characterized by overlapping patents and a strong emphasis on process innovation to boost domestic pharmaceutical manufacturing.
-
Strategic Importance:
The patent's enforceability hinges on its claim breadth and validity; it serves as a critical asset for its owner in safeguarding market share, enforcing rights, or licensing.
-
Legal and Commercial Implications:
As China continues to enhance patent enforcement, patent holders of such process innovations—like CN114712362—must actively defend or leverage their rights to maximize commercial benefits.
-
Global Consideration:
Cross-jurisdictional patenting is advisable for broad protection, especially for drugs with international markets. Similar process patents in key jurisdictions can mitigate risks of generic entry.
FAQs
1. What specific technological innovation does CN114712362 cover?
It pertains to a novel process for manufacturing a particular pharmaceutical composition, likely involving unique steps, conditions, or reagents that improve efficiency or product quality.
2. How broad are the claims under CN114712362?
While the exact wording requires access to the full patent document, Chinese process patents often include broad independent claims limited by specific process parameters, with dependent claims detailing particular embodiments.
3. Can competitors develop alternative manufacturing methods to avoid infringing this patent?
Yes. If claims are narrowly drafted, competitors can innovate around specific process steps; broader claims pose higher barriers to circumventing infringement.
4. How does this patent fit into China's overall pharmaceutical patent environment?
It exemplifies China's shift toward protecting process innovations, which are crucial in the manufacturing sector, especially with government policies favoring domestic drug development.
5. What should patent applicants consider when drafting similar patents?
Clarity, claim breadth, and specificity are vital. Including multiple dependent claims enhances protection, and drafting claims that balance broad coverage with patentability improves enforceability.
References
[1] China National Intellectual Property Administration. Patent CN114712362.
[2] World Intellectual Property Organization. Patent Landscape Reports – Chinese Pharmaceutical Patents.
[3] China’s Patent Law and Guidelines (latest amendments).
[4] Industry Reports on Chinese Pharmaceutical Patent Trends (2022).
